agenus inc (AGEN:NASDAQ CM)
Transactions by AGENUS INC (AGEN) in the last 6 months
Agenus Inc. (NasdaqCM:AGEN) acquired rights of Carcinoembryonic Antigen Cell Adhesion Molecule 1 from DIATHEVA s.r.l. for $44 million on July 20, 2015. Under the terms of the agreement, the consideration involves certain upfront, early development, clinical trial and regulatory milestone payments for the successful development of CEACAM1 antibodies totaling as much as $44 million. Diatheva is also eligible to receive additional sales milestones and royalties. Brad Miles ...
Agenus Inc. (NasdaqCM:AGEN) acquired assets of Celexion, LLC from Flagship Ventures Fund 2007 LP fund of Flagship Ventures, Brian M. Baynes and Alexandria Equities, LLC for $10 million on April 7, 2015. Included in the asset acquisition is the SECANT(R) yeast display platform for the generation of novel monoclonal antibodies, key antibody assets, Celexion's novel approaches to generate antibodies against membrane bound protein targets such as GPCRs and ion channels. ...
Flagship Ventures Fund 2007, L.P.
|No competitor information is available for AGEN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|